SNY Stock Recent News

Online availability of Sanofi's half-year financial report for 2024 Paris, July 25, 2024. Sanofi announces that its half-year financial report for the period ending June 30, 2024 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K.

Sanofi's second-quarter profit rose 3.2% on strong demand for its blockbuster asthma drug Dupixent and better-than-expected sales of new launches, with the company now expecting a stable full-year profit compared to a prior forecast of a fall.

NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A ALTUVIIIO provides high-sustained factor levels with once-weekly dosing in children under 12 with hemophilia A XTEND-Kids results show highly effective bleed protection in hemophilia A with no inhibitor development to factor VIII Paris, July 17, 2024 – Full results from the XTEND-Kids phase 3 study published in The New England Journal of Medicine (NEJM) highlights the efficacy, safety, and pharmacokinetic profile of ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein]. ALTUVIIIO (efanesoctocog alfa), a first-in-class, high-sustained factor VIII replacement therapy, is approved for adults and children with hemophilia A for routine prophylaxis and on-demand treatment to control bleeding episodes as well as for perioperative management (surgery).

French drugmaker Sanofi plans to invest 400 million euros ($437.24 million) in its global capacity centre (GCC) in India by the end of the decade, as it aims to expand and more than double its workforce over the next two years, a top company executive said on Wednesday.

Customers will start receiving shipments from July 10 with additional shipments through October to healthcare provider offices, pharmacies and other immunizers to support fall immunization campaigns. Sanofi annual higher-dose influenza (flu) vaccinations have been proven to help protect from flu and shown to better protect from serious complications of flu such as pneumonia and cardiac events when compared to standard dose vaccines in older adults.

Shares of Kymera Therapeutics (KYMR) jumped Tuesday, a day after it said partner Sanofi (SNY) agreed to extend a Phase 2 trial of its experimental drug to treat certain autoimmune skin diseases.

Bpifrance Executive Director Jose Gonzalo said that the public investment bank is considering a potential investment in Sanofi's consumer health unit, Bloomberg News reported on Thursday.

Stock spinoffs typically don't do well initially. Unloved by shareholders of the former parent company, often misunderstood by the market and sometimes laden with debt or other baggage the parent no longer wanted to carry, spinoff stocks can take time to find their footing.

Sanofi CEO Paul Hudson joins Caroline Hyde to discuss the company's integration of AI tools in everyday operations, the impact of AI on the biopharma sector, and the company's Dupixent drug getting cleared for a chronic lung disorder in the European Union, creating another avenue of growth for the blockbuster drug. He speaks on "Bloomberg Technology.

Sanofi and partner Regeneron on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a chronic lung disease, a rare case of the EU clearing a drug faster than the United States.